Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
The repeated daily administration of GSBR-1290 at doses up to 120 mg exhibited an overall good safety and tolerability profile
Your physician and our care team will reach out to your insurer on your behalf, and this process can take several business days
Combination in patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment with Metformin alone, Sulfonylurea alone, Basal Insulin alone or Metformin in Combination with either Sulfonylurea or Basal Insulin In a 26-week, double-blind trial (Trial 5, NCT02827708), 324 adult patients with moderate renal impairment (eGFRCKD-EPI 30 to 59 mL/min/1.73 m2) were randomized to semaglutide tablets 14 mg orally once daily or placebo once daily
Relation of synovitis to knee pain using contrast-enhanced MRIs
US$ 21.19
US$ 29.58
US$ 21.47
US$ 25.84
US$ 28.26
US$ 29.83
US$ 27.69
US$ 24.72
US$ 27.18
